Search
In 2024, the MSK Giving community raised $511 million to advance MSK’s mission of ending cancer for life — every single dollar donated is making a real difference in the way we treat and understand cancer.
Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions.
Androgen-deprivation therapy, a mainstay of prostate cancer treatment, may give prostate cells new growth abilities, scientists at Memorial Sloan Kettering have found.
A new imaging technology developed at MSK allows researchers to focus on genes as they are copied into messenger RNA.
The summer programs connect high school and medical school students with MSK faculty while offering the opportunity for student-to-student mentorship.
The Nobel committee this week awarded its Prize in Physiology or Medicine to work focused on cancer, specifically, James P. Allison and Tasuku Honjo for their work on immune checkpoint blockade. Dr. Allison was a member of the Sloan Kettering Institute from 2004 to 2012.
A number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.
Human data and results from mouse experiments suggest that people with BRCA2 mutations may respond well to immunotherapy drugs.
A clinical trial provides evidence that blocking a protein called PI3K can be an effective treatment strategy for breast cancer.